Gland Pharma Share Price in Focus as Visakhapatnam Facilities Clear USFDA Inspection With Zero Observations

Gland Pharma share price rose 0.20 percent to Rs 2,874.20 on 2 September 2026, after the company confirmed that its Visakhapatnam Special Economic Zone sterile oncology formulations facility and API facility had cleared a routine US Food and Drug Administration inspection without any Form 483 observations. The inspection was carried out between 24 August and 1 September 2026.

A zero-observation USFDA inspection outcome is a meaningful positive for Gland Pharma share price, since it removes near-term uncertainty around potential warning letters or import alerts that can disrupt supply to key US customers.

Click Here – Get Free Investment Predictions

What Did the USFDA Inspection at Gland Pharma Cover?

The United States Food and Drug Administration conducted a routine Good Manufacturing Practice inspection at Gland Pharma's Visakhapatnam Special Economic Zone sterile oncology formulations facility and its API facility between 24 August and 1 September 2026. The inspection concluded with zero Form 483 observations, indicating the regulator found no deficiencies requiring corrective action at either facility.

Why Does a Clean USFDA Inspection Matter for Gland Pharma Share Price?

Gland Pharma share price is closely tied to the company's significant reliance on the US market, where regulatory compliance directly affects its ability to manufacture and supply products. A history of clean facility inspections, without major warning letters, has been a key differentiator for Gland Pharma share price within the Indian generic injectables space.

Gland Pharma share price has historically seen sharp single-day moves around USFDA news. Trading volumes on 2 September 2026 stood at 87,170 shares, an increase of 603.98 percent over the five-day average of 12,382 shares, reflecting market attention to the development.

Gland Pharma Company Overview and Valuation

Gland Pharma share price reflects a market capitalisation of around Rs 47,318 crore and a price to earnings ratio of 41.92, above the pharma sector average of 38.05. Return on equity stands at 9.92 percent, and the company operates as a subsidiary of China's Fosun Pharma, with a footprint spanning over 60 countries.

Check Live Stock Data on the Univest Screener

What Should Investors Watch for Gland Pharma Going Forward?

Investors tracking Gland Pharma share price should watch for the Establishment Inspection Report that typically follows a clean USFDA visit, as well as progress on product registrations, where the company already has over 1,400 across international markets. Quarterly execution in Europe and the US remains an important catalyst for Gland Pharma share price.

Conclusion

Gland Pharma share price edged higher on 2 September 2026 after its Visakhapatnam facilities cleared a USFDA inspection with zero Form 483 observations, a clean outcome that reduces regulatory risk for a company reliant on the US injectables market. Gland Pharma share price saw trading volumes surging well above average, reflecting investor attention. Investors should assess valuation and consult a SEBI-registered advisor before making investment decisions.

Download the Univest iOS App or Univest Android App to track live prices and get daily stock updates.

Frequently Asked Questions

Why did Gland Pharma share price rise today?

Ans. Gland Pharma share price rose 0.20 percent on 2 September 2026 after the company's Visakhapatnam sterile oncology and API facilities cleared a routine USFDA inspection with zero Form 483 observations.

What is a Form 483 observation?

Ans. A Form 483 observation is a notice issued by the USFDA when inspectors observe conditions that may violate Good Manufacturing Practice requirements. A zero-observation outcome means no such deficiencies were found during the inspection.

When was the USFDA inspection at Gland Pharma's Visakhapatnam facility conducted?

Ans. The USFDA inspection at Gland Pharma's Visakhapatnam Special Economic Zone facilities was conducted between 24 August and 1 September 2026.

What is Gland Pharma's current market capitalisation?

Ans. Gland Pharma's market capitalisation stood at approximately Rs 47,318 crore as of the latest available data.

Why does the US market matter so much for Gland Pharma?

Ans. Gland Pharma is a generic injectables focused company with significant reliance on the US market, where regulatory compliance directly affects its ability to manufacture and supply products to customers.

What is Gland Pharma's price to earnings ratio?

Ans. Gland Pharma trades at a price to earnings ratio of around 41.92, above the broader pharma sector average of 38.05.

What typically follows a clean USFDA inspection?

Ans. A clean USFDA inspection is typically followed by an Establishment Inspection Report confirming closure of the inspection, which further reduces regulatory uncertainty for the company.